AST 120

01/01/2009 - "This finding suggests that AST-120 treatment is effective in slowing the progression of chronic kidney disease, especially, in patients who exhibit a poor response to standard care."
01/01/2021 - "Efficacy of AST-120 for Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials."
09/01/2005 - "We are conducting a clinical trial to investigate the efficacy of an oral carbonaceous adsorbent (Kremezin) in patients at the predialysis stage of progressive chronic kidney disease (the Carbonaceous oral Adsorbent's effectiveness on Progression of chronic Kidney Disease [CAP-KD] trial). "
11/01/2019 - "Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients."
06/01/2015 - "AST-120 ameliorates lowered exercise capacity and mitochondrial biogenesis in the skeletal muscle from mice with chronic kidney disease via reducing oxidative stress."

01/01/2009 - "The results suggest that long-term treatment with AST-120 may be beneficial for chronic renal failure patients in the pre-dialysis stage."
07/01/1999 - "We have reported that oral sorbent AST-120 (AST) is effective in delaying the induction of dialysis in patients with chronic renal failure (CRF) because of its effect on lipid metabolism. "
01/01/1992 - "The results indicate that AST-120 is effective in the treatment of chronic renal failure in terms of reducing uremic symptoms as well as preserving renal function and glomerular architecture. "
06/01/2003 - "Although it has been repeatedly shown that the oral carbonaceous absorbent AST-120 ameliorates the progression of chronic renal failure, the mechanisms remain unknown. "
01/01/2009 - "This study evaluated the long-term effects of AST-120 in patients with chronic renal failure who had not previously undergone dialysis. "

05/01/2000 - "Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta(1) expression in spontaneously diabetic (OLETF) rats."
12/10/2021 - "Our results demonstrated IS potentiates renal fibrosis, senescence-associated secretory phenotype (SASP), and activation of endoplasmic reticulum (ER) stress, which is attenuated by synergistic AST-120 administration. "
01/01/2013 - "IS levels can be reduced by administration of the oral adsorbent AST-120, which has been shown to ameliorate pathological renal and cardiac fibrosis in moderate to severe CKD. "
01/01/2012 - "Reduction of IS with AST-120 normalizes cardiac fibrosis, in a blood pressure independent manner."
01/01/2012 - "We conclude that AST-120 ameliorated EMT and interstitial fibrosis in the kidneys of CKD rats, probably by alleviating IS overload on the kidneys."

04/22/2019 - "However, it is unclear whether the addition of AST-120 to conventional treatments is effective in delaying the progression of renal dysfunction in patients with diabetic nephropathy. "
04/22/2019 - "Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study."
11/01/2010 - "Data were obtained from randomized trials estimating the progression of diabetic nephropathy with and without AST-120, and published literature. "
04/22/2019 - "The addition of AST-120 to conventional treatments may delay the progression of renal dysfunction in diabetic nephropathy. "
09/01/2008 - "Thus, we concluded that administration of AST-120 initiated in early stage overt diabetic nephropathy stunts the progression of renal dysfunction."

01/01/2020 - "These collective data suggest IS could be a therapeutic target for the CKD-related inflammatory response in adipose tissue, and that AST-120 could be useful for the treatment of IS-induced adipose tissue inflammation."
10/17/2018 - "In this study, we demonstrated that sera of CKD patients induced a significant inflammation in astrocyte cells which was proportional to IS sera concentrations, and that the IS adsorbent, AST-120, reduced this inflammatory response. "
06/01/2013 - "We aimed to determine whether AST-120 improves monocyte-mediated inflammation through IS reduction. "
05/01/2011 - "Early treatment with AST-120 significantly decreased both parameters, and this was accompanied by improved renal function and decreased interstitial inflammation, fibrosis, and apoptotic cell death compared with those of rats that received CsA alone. "
10/09/2015 - "AST-120 treatment significantly alleviated renal dysfunction-induced oxidative stress, inflammation, and atrial fibrosis and, consequently, attenuated AF inducibility. "